📰 Priority Review News
Page 32 - Priority Review News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Priority Review. Real-time updates on events, politics, business and more.
November 8, 2023
Announced on November 8, 2023, the approval of tirzepatide(Zepbound) was awarded to Eli Lilly and Company and represents the first chronic weight management approval for a dual GLP-1/GIP receptor agonist.
November 8, 2023
Drug is intended for persons who are considered 'obese,' and deal with what is called chronic weight management issues.
November 8, 2023
OSAKA, Japan & CAMBRIDGE, Mass., November 08, 2023--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved FRUZAQLA™ (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. FRUZAQLA is the first and onl...
November 8, 2023
Drug is intended for persons who are considered 'obese,' and deal with what is called chronic weight management issues.
November 8, 2023
Drug is intended for persons who are considered 'obese,' and deal with what is called chronic weight management issues.
November 8, 2023
Drug is intended for persons who are considered 'obese,' and deal with what is called chronic weight management issues.
November 8, 2023
Drug is intended for persons who are considered 'obese,' and deal with what is called chronic weight management issues.
November 8, 2023
Drug is intended for persons who are considered 'obese,' and deal with what is called chronic weight management issues.
November 8, 2023
Drug is intended for persons who are considered 'obese,' and deal with what is called chronic weight management issues.
November 8, 2023
Drug is intended for persons who are considered 'obese,' and deal with what is called chronic weight management issues.